Professor Line Bjørge is currently head of the Gynecologic Oncology Unit at the Women’s Clinic, Haukeland University Hospital, a European Training Center in Gynecological Oncology and professor at the University of Bergen.
Bjørge received her medical degree and PhD degree from the University of Bergen and her MBA degree from the Mannheim Business School and ESSEC, Paris. She performed her residency in Obstetrics and Gynecology at Haukeland University Hospital and her postdoc-research training in Bergen, Helsinki and Innsbruck. She serves on the boards of Onkologisk Forum and the Nordic Society of Gynaecological Oncology (NSGO) and is member of the translational research group in the Gynecologic Cancer Inter-Group (GCIG).
The focus of her early research work was immune therapy of ovarian cancer with the use of complement activating monoclonal antibodies. Together with her Finnish mentor, Professor Seppo Meri, she discovered resistance mechanisms and developed methods to overcome them. The last decade, her research portfolio has been more translational and she has developed a large multidisciplinary research portfolio, entitled “Precision Medicine in Ovarian Cancer” where the aim is to translate data from comprehensive molecular profiling into clinical meaningful strategies to improve prevention and individualized patient care.
The main focus for the translational research portfolio is biomarker studies, preclinical models and early phase clinical studies. Bjørge is also principal investigator for two projects funded by the European Commission and is national coordinator for different international phase II and III studies focusing on treatment of gynecological cancer.
The group’s current main interest is surgical management of ovarian cancer. Based on improved understanding of how the extent of cytoreduction is influenced by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach, the group aims to better define the value of cytoreduction and to use this knowledge to develop more individualized therapy. This project has recently received funding from the regional health authorities, Helse-Vest HF.